Skip to main content
Top
Published in: Archives of Gynecology and Obstetrics 3/2020

01-03-2020 | Breast Cancer | Gynecologic Oncology

Survivors of primary breast cancer 5 years after surgery: follow-up care, long-term problems, and treatment regrets. Results of the prospective BRENDA II-study

Authors: Elena Leinert, Rolf Kreienberg, Achim Wöckel, Thorsten Kühn, Felix Flock, Ricardo Felberbaum, Wolfgang Janni, Kathy Taylor, Susanne Singer, Lukas Schwentner, BRENDA study group

Published in: Archives of Gynecology and Obstetrics | Issue 3/2020

Login to get access

Abstract

Purpose

This study aims to answer the questions where breast cancer patients in Germany receive follow-up care (with what types of doctors) and what are the long-term problems and treatment regrets of breast cancer patients.

Methods

In the prospective multicenter cohort study BRENDA II (“Breast Cancer under Evidence-Based Guidelines”), 456 patients with primary breast cancer were sampled consecutively over a period of 4 years (2009–2012) and contacted again 5 years after surgery. Long-term problems were elicited on a 4-point Likert scale ranging from 0 (‘not at all’) to 3 (‘very much’).

Results

82% of the patients receive follow-up (FU) at the private practice gynecologist. In 22%, the initial treating hospital is involved in the FU, and in 20% the general practitioner does this (multiple answers possible). Long-term problems attributed to the treatment were most often related to endocrine therapy (mean 1.29) and to chemotherapy (mean 0.94).
Most of the patients were happy to have had radiotherapy (95%). For chemotherapy, endocrine therapy, and antibody therapy, the satisfaction for the treatment decision was 87%, 87%, and 84% respectively. Among patients who reported they regretted having undergone a recommended treatment, it was most often for endocrine therapy (5%) and chemotherapy (4%).

Conclusion

In Germany, different specialists are involved in the patients’ FU care for BC. The detection of long-term problems due to BC treatment is an essential part of FU care.
Literature
2.
go back to reference Van Ewijk R, Schwentner L, Wöckel A (2013) Trends in patient characteristics, treatment and survival in breast cancer in a non-selected retrospective clinical cohort study of 2,600 patients. Arch Gynecol Obstet 287(1):103–110CrossRefPubMed Van Ewijk R, Schwentner L, Wöckel A (2013) Trends in patient characteristics, treatment and survival in breast cancer in a non-selected retrospective clinical cohort study of 2,600 patients. Arch Gynecol Obstet 287(1):103–110CrossRefPubMed
3.
go back to reference Van Luijt PA, Fracheboud J, Heijnsdijk EA, National evaluation team for breast cancer screening in Netherlands study groups (NETB) (2013) Nation-wide data on screening performance during the transition to digital mammography: observations in 6 million screens. Eur J Cancer 49(16):3517–3525CrossRefPubMed Van Luijt PA, Fracheboud J, Heijnsdijk EA, National evaluation team for breast cancer screening in Netherlands study groups (NETB) (2013) Nation-wide data on screening performance during the transition to digital mammography: observations in 6 million screens. Eur J Cancer 49(16):3517–3525CrossRefPubMed
4.
go back to reference Wo JY, Chen K, Neville BA (2011) Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. J Clin Oncol 29(19):2619–2627CrossRefPubMedPubMedCentral Wo JY, Chen K, Neville BA (2011) Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. J Clin Oncol 29(19):2619–2627CrossRefPubMedPubMedCentral
5.
go back to reference Khatcheressian JL, Hurley P, Bantug E et al (2013) Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(7):961–965CrossRefPubMed Khatcheressian JL, Hurley P, Bantug E et al (2013) Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(7):961–965CrossRefPubMed
9.
go back to reference Schwentner L, Van Ewijk R, Kurzeder C, Hoffmann I, König J, Kreienberg R, Blettner M, Wöckel A (2013) Participation in adjuvant clinical breast cancer trials: does study participation improve survival compared to guideline adherent adjuvant treatment? A retrospective multi-centre cohort study of 9,433 patients. Eur J Cancer 49(3):553–563CrossRefPubMed Schwentner L, Van Ewijk R, Kurzeder C, Hoffmann I, König J, Kreienberg R, Blettner M, Wöckel A (2013) Participation in adjuvant clinical breast cancer trials: does study participation improve survival compared to guideline adherent adjuvant treatment? A retrospective multi-centre cohort study of 9,433 patients. Eur J Cancer 49(3):553–563CrossRefPubMed
10.
go back to reference Hancke K, Denkinger MD, König J (2010) Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study. Ann Oncol 21(4):748–753CrossRefPubMed Hancke K, Denkinger MD, König J (2010) Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study. Ann Oncol 21(4):748–753CrossRefPubMed
11.
go back to reference Galea MH, Blamey RW, Elston CE (1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22:207–219CrossRefPubMed Galea MH, Blamey RW, Elston CE (1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22:207–219CrossRefPubMed
13.
go back to reference Dahlhaus A, Vanneman N, Guethlin C (2014) German general practitioners’ views on their involvement and role in cancer care: a qualitative study. Fam Pract 31:209–214CrossRefPubMed Dahlhaus A, Vanneman N, Guethlin C (2014) German general practitioners’ views on their involvement and role in cancer care: a qualitative study. Fam Pract 31:209–214CrossRefPubMed
14.
go back to reference Sisler J, Chaput G, Sussman J, Ozokwelu E (2016) Follow-up after treatment for breast cancer: practical guide to survivorship care for family physicians. Can Fam Physician 62:805–811PubMedPubMedCentral Sisler J, Chaput G, Sussman J, Ozokwelu E (2016) Follow-up after treatment for breast cancer: practical guide to survivorship care for family physicians. Can Fam Physician 62:805–811PubMedPubMedCentral
15.
go back to reference Leinert E, Singer S, Janni W (2017) The impact of age on quality of life in breast cancer patients receiving adjuvant chemotherapy: a comparative analysis from the prospective multicenter randomized ADEBAR trial. Clin Breast Cancer 17(2):100–106CrossRefPubMed Leinert E, Singer S, Janni W (2017) The impact of age on quality of life in breast cancer patients receiving adjuvant chemotherapy: a comparative analysis from the prospective multicenter randomized ADEBAR trial. Clin Breast Cancer 17(2):100–106CrossRefPubMed
16.
go back to reference Grunfeld E, Levine MN, Julian JA (2006) Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol 24(6):848–855CrossRefPubMed Grunfeld E, Levine MN, Julian JA (2006) Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol 24(6):848–855CrossRefPubMed
17.
go back to reference Dahlhaus A, Vanneman N, Siebenhofer A (2013) Involvement of general practitioners in palliative cancer care: a qualitative study. Support Care Cancer 21(12):3293–3300CrossRefPubMed Dahlhaus A, Vanneman N, Siebenhofer A (2013) Involvement of general practitioners in palliative cancer care: a qualitative study. Support Care Cancer 21(12):3293–3300CrossRefPubMed
18.
go back to reference Tao JJ, Visvanathan K, Wolff AC (2015) Long term side effects of adjuvant chemotherapy in patients with early breast cancer. Breast (Edinburgh, Scotland) 24(02):S149–S153CrossRef Tao JJ, Visvanathan K, Wolff AC (2015) Long term side effects of adjuvant chemotherapy in patients with early breast cancer. Breast (Edinburgh, Scotland) 24(02):S149–S153CrossRef
19.
go back to reference Singer S, Blettner M, Kreienberg R (2015) Breast cancer patients' fear of treatment: results from the Multicenter Longitudinal Study BRENDA II. Breast Care (Basel) 10(2):95–100CrossRef Singer S, Blettner M, Kreienberg R (2015) Breast cancer patients' fear of treatment: results from the Multicenter Longitudinal Study BRENDA II. Breast Care (Basel) 10(2):95–100CrossRef
20.
go back to reference Fernandes-Taylor S, Bloom JR (2011) Post-Treatment regret among young breast cancer survivors. Psycho-oncol 20(5):506–516CrossRef Fernandes-Taylor S, Bloom JR (2011) Post-Treatment regret among young breast cancer survivors. Psycho-oncol 20(5):506–516CrossRef
21.
go back to reference Akechi T, Okuyama T, Endo C (2010) Anticipatory nausea among ambulatory cancer patients undergoing chemotherapy: prevalence, associated factors, and impact on quality of life. Cancer Sci 101:2596–2600CrossRefPubMed Akechi T, Okuyama T, Endo C (2010) Anticipatory nausea among ambulatory cancer patients undergoing chemotherapy: prevalence, associated factors, and impact on quality of life. Cancer Sci 101:2596–2600CrossRefPubMed
23.
go back to reference Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816CrossRefPubMedPubMedCentral Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816CrossRefPubMedPubMedCentral
25.
go back to reference DiSipio T, Rye S, Newman B, Hayes S (2013) Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and metaanalysis. Lancet Oncol 14:500–515CrossRefPubMed DiSipio T, Rye S, Newman B, Hayes S (2013) Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and metaanalysis. Lancet Oncol 14:500–515CrossRefPubMed
26.
go back to reference Kuehn T, Klauss W, Darsow M (2000) Long-term morbidity following axillary dissection in breast cancer patients—clinical assessment, significance for life quality and the impact of demographic, oncologic and therapeutic factors. Breast Cancer Res Treat 64(3):275–286CrossRefPubMed Kuehn T, Klauss W, Darsow M (2000) Long-term morbidity following axillary dissection in breast cancer patients—clinical assessment, significance for life quality and the impact of demographic, oncologic and therapeutic factors. Breast Cancer Res Treat 64(3):275–286CrossRefPubMed
27.
go back to reference Janni W, Kuehn T, Schwentner L et al (2014) Sentinel node biopsy and axillary dissection in breast cancer—the evidence and its limits. Dtsch Arztebl Int 111(14):244–249PubMedPubMedCentral Janni W, Kuehn T, Schwentner L et al (2014) Sentinel node biopsy and axillary dissection in breast cancer—the evidence and its limits. Dtsch Arztebl Int 111(14):244–249PubMedPubMedCentral
28.
go back to reference Giuliano AE, McCall L, Beitsch P et al (2010) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 252:426–432PubMedPubMedCentral Giuliano AE, McCall L, Beitsch P et al (2010) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 252:426–432PubMedPubMedCentral
29.
go back to reference Shaitelman SF, Schlembach PJ, Arzu I et al (2015) Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation: a randomized clinical trial. JAMA Oncol 1:931–941CrossRefPubMedPubMedCentral Shaitelman SF, Schlembach PJ, Arzu I et al (2015) Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation: a randomized clinical trial. JAMA Oncol 1:931–941CrossRefPubMedPubMedCentral
30.
go back to reference Whelan TJ, Pignol J, Levine MN et al (2010) Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362:513–520CrossRefPubMed Whelan TJ, Pignol J, Levine MN et al (2010) Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362:513–520CrossRefPubMed
31.
go back to reference Piccart-Gebhart MJ, Procter M, Leyland-Jones B (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672CrossRefPubMed Piccart-Gebhart MJ, Procter M, Leyland-Jones B (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672CrossRefPubMed
32.
go back to reference Romond EH, Perez EA, Bryant J (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684CrossRefPubMed Romond EH, Perez EA, Bryant J (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684CrossRefPubMed
34.
go back to reference de Azambuja E, Procter MJ, van Veldhuisen DJ et al (2014) Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1–01). J Clin Oncol 32:2159–2165CrossRefPubMed de Azambuja E, Procter MJ, van Veldhuisen DJ et al (2014) Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1–01). J Clin Oncol 32:2159–2165CrossRefPubMed
35.
go back to reference Cameron D, Piccart-Gebhart MJ, Gelber RD (2017) 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389(10075):1195–1205CrossRefPubMedPubMedCentral Cameron D, Piccart-Gebhart MJ, Gelber RD (2017) 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389(10075):1195–1205CrossRefPubMedPubMedCentral
Metadata
Title
Survivors of primary breast cancer 5 years after surgery: follow-up care, long-term problems, and treatment regrets. Results of the prospective BRENDA II-study
Authors
Elena Leinert
Rolf Kreienberg
Achim Wöckel
Thorsten Kühn
Felix Flock
Ricardo Felberbaum
Wolfgang Janni
Kathy Taylor
Susanne Singer
Lukas Schwentner
BRENDA study group
Publication date
01-03-2020
Publisher
Springer Berlin Heidelberg
Published in
Archives of Gynecology and Obstetrics / Issue 3/2020
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-020-05437-1

Other articles of this Issue 3/2020

Archives of Gynecology and Obstetrics 3/2020 Go to the issue

Gynecologic Endocrinology and Reproductive Medicine

Mucin gene polymorphisms are associated with endometriosis in Korean women